Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q1 FY25
Investor Presentation
Q1 FY24
Investor Presentation
Q4 FY22
Bearish
3
Neutral
7
Bullish
4
Bearish
23
Neutral
7
Bullish
16
Bearish
20
Neutral
0
Bullish
12
Bearish
3
Neutral
7
Bullish
4
Bearish
3
Neutral
7
Bullish
4
Bearish
20
Neutral
0
Bullish
12
Bearish
20
Neutral
0
Bullish
12
Bearish
20
Neutral
0
Bullish
12
Upcoming Result Date: Oct 22, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. It focuses on providing affordable and innovative medicines across major therapeutic areas such as oncology, gastrointestinal, and cardiovascular.
The company demonstrated a 4.4% year-on-year revenue growth in Q3FY26, despite facing headwinds from lower sales in certain product lines like Lenalidomide, showcasing its underlying business strength.
Dr. Reddy's is making significant advancements in its biotechnology pipeline, with successful biosimilar launches and strategic regulatory approvals in multiple international markets.
The firm has embarked on strategic collaborations for innovative drug developments and expanded its generics and biosimilars portfolio across emerging and developed markets.
Dr. Reddy's commitment to ESG and sustainability is evidenced by its pledge for science-based net-zero targets by FY2045 and achievements in water security and climate change leadership.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,00,170 Cr
Low Risk
31.1
37.0
-0.7
2.6
1,414.40
1,080.05
Sales CAGR
Profit CAGR
ROE
ROCE
Dr Reddys Laboratories Ltd (DRREDDY) is currently trading at 1,200.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. It focuses on providing affordable and innovative medicines across major therapeutic areas such as oncology, gastrointestinal, and cardiovascular. The company demonstrated a 4.4% year-on-year revenue growth in Q3FY26, despite facing headwinds from lower sales in certain product lines like Lenalidomide, showcasing its underlying business strength. Dr. Reddy's is making significant advancements in its biotechnology pipeline, with successful biosimilar launches and strategic regulatory approvals in multiple international markets. The firm has embarked on strategic collaborations for innovative drug developments and expanded its generics and biosimilars portfolio across emerging and developed markets. Dr. Reddy's commitment to ESG and sustainability is evidenced by its pledge for science-based net-zero targets by FY2045 and achievements in water security and climate change leadership.
Over the past 52 weeks, Dr Reddys Laboratories Ltd has traded between a low of ₹1,080.05 and a high of ₹1,414.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Reddys Laboratories Ltd has a market capitalization of approximately 1,00,169.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Reddys Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.09 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,00,169.98 Cr, Dr Reddys Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Reddys Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Reddys Laboratories Ltd is 31.09. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
USFDA accepted for review Dr. Reddy’s 351(k) Biologics License Application (BLA) for DRL_AB, an IV for infusion formulation proposed as an interchangeable biosimilar to Orencia (abatacept).
Dr. Reddy’s will release Q1 FY27 results on July 22, 2026, and host an earnings call the same day at 19:30 PM IST (10:00 AM ET).
The company said certain batches were found “out of specification” due to a quality-related issue linked to the active pharmaceutical ingredient (API) used in the product.
The company said certain batches of semaglutide API were found to be “out of specification,” prompting an investigation and corrective measures to ensure product quality.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1145.25 | 1,14,239 Cr | 25.43 | 4.21 | 0.09 | 18.59 | 17.35 | 8.57 | ||
1346.85 | 1,08,808 Cr | 32.34 | 3.16 | 0.97 | 11.27 | 14.95 | 7.92 | ||
1989.00 | 1,07,468 Cr | 98.53 | 20.28 | 0.10 | 16.77 | 16.14 | 10.38 | ||
2527.00 | 1,04,376 Cr | 50.48 | 6.40 | 0.04 | 11.74 | 13.13 | 7.36 | ||
1200.10 | 1,00,170 Cr | 31.47 | 2.63 | 0.67 | 11.07 | 12.54 | 5.48 | ||
1675.00 | 96,376 Cr | 25.97 | 2.54 | 0.24 | 9.25 | 11.76 | 6.34 | ||
2029.00 | 92,784 Cr | 16.71 | 4.13 | 0.89 | 23.76 | 24.88 | 14.47 | ||
| Median: 7 Co. | — | 1675.00 | 1,04,376 Cr | 31.47 | 4.13 | 0.24 | 11.74 | 14.95 | 7.92 |
